IVF Protocols and Medications: How Doctors Choose a Plan
Key Takeaways
An IVF protocol is a plan for growing eggs and timing retrieval. It also guides how to prevent early ovulation and reduce ovarian hyperstimulation syndrome (OHSS) risk. The plan depends on your ovarian response and treatment goals; it cannot guarantee a specific result.
Key evidence: ESHRE — Ovarian stimulation for IVF/ICSI guideline (2025 update)
When patients receive their IVF medication calendar, the list of daily injections, nasal sprays, and tablets can feel daunting. It is natural to focus on the names and dosages of the drugs. But in fertility medicine, the underlying clinical logic matters far more than the brand on the box.
An IVF protocol is a treatment plan tailored to the person. The same hormone medicine can be used differently depending on age, ovarian reserve tests, previous response, and diagnosis. Examples include polycystic ovary syndrome (PCOS) and endometriosis. Antral follicle count (AFC) is the number of small follicles seen on ultrasound. Anti-Müllerian hormone (AMH) is a blood test used to estimate ovarian reserve.
Knowing why a protocol was chosen can make the medication plan easier to follow and discuss with your fertility specialist.
What is an IVF protocol designed to achieve?
Short answer: An IVF protocol aims to mature a useful group of eggs while preventing early ovulation and lowering the risk of moderate or severe OHSS.
The goal is not simply to maximise the number of eggs. A high ovarian response is also linked to a higher risk of ovarian hyperstimulation syndrome (OHSS), so the plan has to balance response and safety. The ASRM guideline on OHSS prevention recommends individualising gonadotropin doses and using risk-reduction strategies for patients at increased risk. A protocol also has to:
- recruit a useful group of follicles for your ovarian reserve
- prevent a surge in luteinizing hormone (LH) before the eggs are ready
- reduce OHSS risk, especially for patients with PCOS or a high response
- allow the team to respond if follicles grow faster or slower than expected
- fit the transfer plan: fresh transfer or freeze-all, where embryos are frozen for later
The 2025 ESHRE guideline on ovarian stimulation includes recommendations on ovarian reserve assessment, stimulation, monitoring, and OHSS prevention. Ovarian reserve tests help clinicians estimate response and plan treatment; they do not determine an individual outcome on their own.
Common IVF stimulation protocols
Different protocols control the timing of follicle recruitment and prevent premature ovulation through distinct hormonal mechanisms.
1. The gonadotropin-releasing hormone (GnRH) antagonist protocol (a common modern first-line choice)
Short answer: The 2025 ESHRE guideline recommends GnRH antagonist protocols over agonist protocols for the general IVF/ICSI population because efficacy is comparable and safety is higher. For patients at risk of OHSS, an antagonist cycle also allows a GnRH agonist trigger; a freeze-all plan can further reduce that risk.
In a common version of this protocol, gonadotropin stimulation starts early in the menstrual cycle. A gonadotropin-releasing hormone (GnRH) antagonist is added later to prevent a premature luteinizing hormone (LH) surge. The exact start day depends on the protocol and monitoring findings.
In some patients, this protocol’s practical features include:
- it avoids the longer pituitary-suppression phase used in a long agonist protocol
- it allows a GnRH agonist trigger when appropriate, particularly when OHSS risk is elevated
- a freeze-all strategy can further lower OHSS risk when clinically indicated
The ASRM guideline recommends antagonist-based stimulation when OHSS risk is a concern. This can be relevant for patients with polycystic ovary syndrome, though the choice depends on the person’s history and treatment plan.
2. The long GnRH agonist protocol
Short answer: A long GnRH agonist protocol suppresses pituitary hormone activity before ovarian stimulation. It can help with cycle scheduling, but it is not the default protocol for every patient.
In one long-protocol schedule, a GnRH agonist is started in the luteal phase of the preceding cycle. It first causes a short rise in pituitary hormones, then suppresses their release. Gonadotropin stimulation begins after suppression is confirmed. Timing and medication schedules vary between protocols.
Compared with an antagonist protocol, the long agonist approach usually takes longer and may involve more medication. Because the ESHRE guideline favours antagonist protocols for the general IVF/ICSI population, a specific reason to use a long protocol should be assessed individually. For endometriosis, the ESHRE endometriosis guideline says no specific stimulation protocol can be recommended and that antagonist or agonist protocols can be offered. It also advises against extended GnRH agonist treatment before IVF solely to improve live-birth rates, because the benefit is uncertain.
3. Progestin-primed ovarian stimulation (PPOS)
Short answer: PPOS uses an oral progestin to prevent a premature LH surge during stimulation. It is an option when embryo transfer is planned for a later cycle.
In PPOS, an oral progestin is taken alongside gonadotropins to suppress the LH surge. The regimen is selected by the treating team.
Because progestin exposure affects the endometrium, PPOS is generally paired with freezing embryos for later transfer. A systematic review and meta-analysis by Cui et al.—an analysis that combines results from several studies—found broadly comparable outcomes with antagonist cycles in the settings studied. The evidence does not establish that the approaches are interchangeable for every patient. The ESHRE guideline considers progestin suppression an option when a freeze-all strategy is planned.
4. DuoStim (dual stimulation in one cycle)
Short answer: DuoStim uses two rounds of stimulation and egg retrieval in one menstrual cycle. It can bring the second retrieval forward, but the one randomised trial in poor responders found no clear gain in eggs or embryos over two conventional cycles.
The first stimulation takes place in the follicular phase. A second stimulation begins in the luteal phase after the first egg retrieval. The timing is set by the clinical team.
DuoStim is generally paired with freezing embryos for transfer in a later cycle. The timing of transfer depends on the treatment plan. The 2025 ESHRE guideline says double stimulation can be used to accumulate oocytes or embryos when a fresh transfer is not planned (strong recommendation, low-certainty evidence), and can be considered for urgent fertility preservation cycles.
In the multicentre BISTIM trial, 88 women with poor ovarian response were randomly assigned to DuoStim or two conventional antagonist cycles. The trial did not find a clear difference in the total number of eggs or embryos. The second retrieval happened sooner with DuoStim (0.3 vs 2.8 months). When women were analysed in the groups they were assigned to, the DuoStim group had fewer embryos transferred per woman (0.9 vs 1.5). That difference was not clear in a second analysis limited to women who followed their assigned treatment. The study did not show a shorter time to pregnancy or a live-birth advantage. Cumulative live birth was numerically lower with DuoStim (17.9% vs 34.1%), but the difference was not statistically clear and the study was too small to settle those outcomes. DuoStim may be discussed when reducing the time between retrievals matters.
5. Random-start stimulation
Short answer: Random-start stimulation can begin outside the early menstrual-cycle window. It is used when fertility preservation is time-sensitive, including before some cancer treatments.
When cancer treatment is time-sensitive, the fertility and oncology teams can discuss whether stimulation can start without waiting for the next menstrual period. A systematic review by Alexander et al. compared random and conventional starts for fertility preservation in women with cancer. The treatment schedule still needs to be coordinated with the oncology team.
Core medication groups in IVF
Understanding what each prescription does helps simplify your daily routine.
Gonadotropins (follicle stimulants)
These medications provide follicle-stimulating hormone (FSH), sometimes combined with luteinizing hormone (LH) activity, to encourage multiple follicles to grow simultaneously:
- Recombinant FSH (rFSH): Pure FSH produced through recombinant DNA technology.
- Human menopausal gonadotropin (hMG): A gonadotropin preparation with FSH and LH activity; its formulation depends on the product.
- Long-acting FSH: A modified molecule providing sustained stimulation over several days with a single injection.
Ovulation blockers (preventing premature LH surge)
These medicines help prevent a premature LH surge, but they work in different ways and are used in different protocols:
- GnRH antagonists: Rapidly bind and block GnRH receptors within hours.
- GnRH agonists: First stimulate, then suppress pituitary receptors when used over an extended period in a long protocol.
- Oral progestins: Provide central feedback suppression during PPOS cycles.
Trigger medications (final oocyte maturation)
The trigger supports final oocyte maturation. Egg retrieval is often scheduled about 34 to 36 hours later, though the exact timing is set by the clinic:
- Recombinant or urinary human chorionic gonadotropin (hCG): Supports final maturation. The choice of trigger depends on the cycle and OHSS risk.
- GnRH agonist trigger: An option in antagonist cycles that reduces the risk of moderate-to-severe OHSS. If a fresh transfer is planned, adequate luteal support is needed; a freeze-all plan may be considered for patients at risk.
- Dual trigger: Combines a GnRH agonist with hCG in selected cases. Adding hCG may increase OHSS risk, so the expected benefit and risk need to be weighed.
Luteal phase support
Progesterone support is commonly prescribed after egg retrieval because stimulation and retrieval can affect luteal-phase hormone production. The exact plan depends on the type of cycle and transfer:
- Progesterone: Administered vaginally, subcutaneously, or intramuscularly to prepare and maintain the receptive endometrium.
- Estrogen: Added in selected frozen embryo transfer protocols or programmed cycles.
Because stimulation medications and luteal support are frequently itemised separately from clinic procedure packages, reviewing how IVF treatment costs are structured helps avoid unexpected expenses.
Why do medication doses change mid-cycle?
Short answer: A dose change during monitoring does not, by itself, mean that something has gone wrong. The team may adjust the plan in response to the cycle.
Ovarian response to gonadotropins varies. During a cycle, ultrasound scans track follicle growth; blood tests may also measure oestradiol and progesterone. The clinic may adjust medication or timing in response to these findings.
Common clinical adjustments include:
- considering a dose change if follicle growth differs from what was expected
- reviewing the plan if hormone levels or follicle growth suggest a higher response
- adjusting the exact start day of the antagonist injection
- considering a GnRH agonist trigger and freeze-all plan when OHSS risk is elevated
To explore the clinical mechanisms behind these adjustments, see our guide on ovarian stimulation in IVF.
Dr. Aksoy’s clinical perspective
Dr. Aksoy’s Approach: Dr. Aksoy does not regard one IVF protocol as universally “best”. His clinical framework starts with ovarian reserve, the previous response, the diagnosis and the safety profile of the current cycle. Antagonist protocols are often a practical starting point because they allow flexible OHSS-reduction strategies. Long agonist protocols, PPOS and DuoStim may be considered for specific clinical reasons. Careful monitoring and proportionate adjustment remain part of the plan.
Questions to discuss with your fertility specialist
- Which stimulation protocol are you recommending for my ovarian reserve, and why?
- What is my estimated risk for ovarian hyperstimulation syndrome?
- Is our baseline strategy a fresh embryo transfer or a planned freeze-all?
- What specific criteria will guide any medication dose changes during monitoring?
- If I had a poor or suboptimal response in a previous cycle, how does this new protocol address that?
To learn more about optimising your treatment parameters, review our evidence-based strategies to improve IVF success and key IVF treatment risks and considerations.
Frequently Asked Questions for Dr. Aksoy
Does the antagonist protocol improve egg quality?
I often use an antagonist protocol, but not because it directly improves egg quality. It gives me more flexibility in planning treatment and can reduce OHSS risk, particularly for patients with PCOS or those expected to have a high ovarian response. Compared with a long protocol, it has not been shown to improve the chromosomal quality of eggs or live-birth outcomes. When I choose a protocol, I consider ovarian reserve, the expected response, and treatment safety together.
Evidence note: The 2025 ESHRE guideline recommends antagonist protocols over agonist protocols for the general IVF/ICSI population because efficacy is comparable and safety is higher. In the 2025 Cochrane network meta-analysis, short antagonist and long agonist protocols probably gave similar live-birth rates in women expected to respond normally (moderate-certainty evidence), and antagonist protocols may reduce OHSS (low-certainty evidence).
What is the clinical difference between Luveris and Menopur?
Luveris contains recombinant LH and is usually used together with an FSH medicine. Menopur has both FSH and LH activity, and much of its LH activity comes from hCG. Their ingredients and use differ, but evidence has not shown one to provide better egg quality or a higher pregnancy chance for every patient. I consider the patient’s hormonal profile, ovarian response, and whether additional LH support is needed.
Evidence note: The EMA product information lists Luveris, given together with an FSH preparation, for stimulating follicle development in women with severe LH and FSH deficiency. That is a narrower licensed use than general IVF stimulation. The UK Menopur 150 IU product information describes FSH and LH bioactivity in a 1:1 ratio, with LH bioactivity driven mainly by hCG. Licensed uses and availability differ between countries.
What does “short protocol” mean in IVF, and when might it be used?
Strictly speaking, “short protocol” refers to protocols that use a GnRH agonist. The term is also used for protocols that use an antagonist, and these are different approaches. In the antagonist version, stimulation starts early in the menstrual cycle and the antagonist is added during stimulation; unlike a long protocol, it does not include several weeks of prior pituitary suppression. I often use the antagonist version when OHSS risk is high, but it can also be used for patients with an expected normal or low response. A short protocol does not, by itself, mean better egg quality.
Sources
- The ESHRE Guideline Group on Ovarian Stimulation. “ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025.” Human Reproduction, 2026;41(4):498-514. ESHRE guideline and evidence tables; PubMed
- The ESHRE Guideline Group on Endometriosis. “ESHRE guideline: endometriosis.” Human Reproduction Open, 2022;2022(2):hoac009. ESHRE endometriosis guideline
- Alexander VM, Martin CE, Schelble AP, et al. “Ovarian stimulation for fertility preservation in women with cancer: A systematic review and meta-analysis comparing random and conventional starts.” Journal of Gynecology Obstetrics and Human Reproduction, 2021;50(8):102080. PubMed
- Massin N, Abdennebi I, Porcu-Buisson G, et al. “The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.” Human Reproduction, 2023;38(5):927-937. Full text; PubMed
- Cui L, Lin Y, Wang F, et al. “Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology: a systematic review and meta-analysis.” Archives of Gynecology and Obstetrics, 2021;303(3):615-630. PubMed
- American Society for Reproductive Medicine. “Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline.” 2023. ASRM
- Melo P, Eapen A, Chung Y, et al. “Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis.” Cochrane Database of Systematic Reviews, 2025;7:CD012586. Cochrane review
- European Medicines Agency. “Luveris: product information.” EMA
- Ferring Pharmaceuticals. “Menopur 150 IU: Summary of Product Characteristics.” Medicines.org.uk
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.